US › Healthcare

Monopar Therapeutics Inc (MNPR)

US · Healthcare · Biotechnology

$118.46+6.11%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-3.9M
Profit YoY
-48.3%
EPS
$-0.46
EPS estimate
$-0.90

EPS came in at -0.46 against a street estimate of -0.90 — a beat of 48.7%.

Key statistics

Market cap
$725.8M
Forward P/E
0.0
P/B
5.35
Book value
$20.21
EPS (TTM)
$-1.93
52-week high
$116.69
52-week low
$29.18
50-day MA
$84.68
200-day MA
$71.04
Beta
1.48

Analyst view

Analysts rate Monopar Therapeutics Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $116.85.

Shareholding

Insiders
23.42%
Institutions
95.51%

Largest institutional holders

FundStake
HHG PLC19.67%
RA Capital Management, LLC9.96%
Saturn V Capital Management LLC5.16%
Deerfield Management Co4.83%
BlackRock Inc4.73%
Adage Capital Partners Gp LLC4.62%
Siren, L.L.C.4.03%
ADAR1 Capital Management LLC3.94%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Monopar Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.